Cloughesy et al. discovered that neoadjuvant anti-PD-1 (pembrolizumab) therapy enhanced CD8 + T cell infiltrate and INFγ-related gene expression in the tumor of recurrent GBM [99]. This evidence concerns the gene RPL17 and neoplasm.